Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Published in:

Advances in Hematology, 2022, p. 1, doi. 10.1155/2022/4450824

By:

• Castro, Januario E.;
• Lengerke-Diaz, Paula A.;
• Velez Lujan, Juliana;
• Choi, Michael Y.;
• Moreno-Cortes, Eider F.;
• Forero, Jose V.;
• Garcia-Robledo, Juan Esteban;
• Jacobs, Chaja;
• McCarthy, Colin;
• Heinen, Alaina;
• Amaya-Chanaga, Carlos I.;
• Kipps, Thomas J.

Publication type:

Article